Clinical Trial

68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-24; most recent amendment 2025-05-29.
Trial Details
NCT Number NCT06387381
Lead Sponsor First Affiliated Hospital of Chongqing Medical University
Conditions PSMA, FAP, Positron-Emission Tomography
Enrollment 30 participants
Start Date 2024-05-20
Primary Completion 2025-04-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-04